NeuroGene Nile

NeuroGene Nile We bridge the gap between local genetic diversity and global neurological knowledge.

NeuroGene Nile (NGN) is Egypt’s first dedicated educational platform focusing on neurogenetics and neurodevelopmental disorders through the lens of Egyptian cases.

From Molecular to Clinical aspect of Rhizomelic Chondrodysplasia Punctata (RCDP)🧬🧠Meet RayanAt two months old, his brain...
22/05/2026

From Molecular to Clinical aspect of Rhizomelic Chondrodysplasia Punctata (RCDP)🧬🧠

Meet Rayan
At two months old, his brain began to misfire: subtle seizures, floppy muscles, and an MRI that revealed fragile, damaged white matter.

The cause wasn’t a large deletion or a dramatic mutation. It was hiding inside a slippery, seven‑letter stutter in his DNA!

In the PEX7 gene, there’s a short word: TGCGGTG
If you look at healthy genomes (check ensembl), you’ll see that word repeated twice, it's a normal genetic stutter in this gene. Almost all of us have it.
But Liam inherited an allele where the stutter kept going, not twice but three times: TGCGGTG TGCGGTG TGCGGTG

That third copy threw the entire gene out of frame.
The PEX7 protein which is a critical import receptor for peroxisomes was truncated almost immediately (p.Ala7GlyfsTer42).
No functional PEX7 means nothing gets into the peroxisome, which subsequently leading to:

The Left Path (Anabolism): The enzymes DHAPAT and AGPS fail to enter the peroxisome. These enzymes catalyze ether lipid synthesis. Their absence causes a profound plasmalogen deficiency. Because plasmalogens are major structural phospholipids in myelin sheaths, this deficiency leads directly to defective myelination.

The Right Path (Catabolism): The enzyme Phytanoyl-CoA hydroxylase (PHYH) is denied entry into the peroxisome. PHYH is required for the alpha oxidation of branched-chain fatty acids, this blockade causes an upstream accumulation of phytanic acid, which is highly cytotoxic to neurons and nervous tissue.

This all explains the white matter changes in the brain and severe developmental delay in RCDP1 patients, merging the genotypic and phenotypic data.

🧬🇪🇬 Canavan Disease Egyptian Case: A 3‑Year Diagnostic Journey.A 4.5-year-old girl presented to our unit with macrocepha...
03/05/2026

🧬🇪🇬 Canavan Disease Egyptian Case: A 3‑Year Diagnostic Journey.

A 4.5-year-old girl presented to our unit with macrocephaly, global hypotonia, head lag, spastic tetraparesis, and seizures. She had been diagnosed with cerebral palsy since age 1, with no genetic workup.
We listened to the history carefully from the parents: “she was fine at birth. At three months, she stopped following me with his eyes. Her head grew too fast, she couldn’t hold his neck. Currently, she can’t sit or speak.”

We knew immediately this was not cerebral palsy!
This was a classic leukodystrophy and the macrocephaly, hypotonia, and head lag pointed toward one specific diagnosis (Canavan disease)

📊Molecular Diagnosis (ASPA gene): revealed that a homozygous c.91G>T (p.Val31Phe) in exon 1 of ASPA gene – a pathogenic variant first reported in an Egyptian patient by Zaki et al. (2015). Parents are carriers and two older siblings died undiagnosed.

(A) Macrocephaly, frontal bossing, hypotonic posture.
(B) MRI: diffuse white matter high signal + globus pallidus involvement.
(C) MRS: striking NAA elevation (NAA/Cr >4).
(D) Sequencing analysis shows a homozygous G >T substitution at position 91 of the ASPA gene of the patient (case), indicated with an arrow, compared to a healthy control.
(E, F) ASPA Protein structural analysis showing the significant difference between valine and phenylalanine, respectively, in the context of chemical class and size (replacing valine with bulky side chain of Phe causes local distortion or steric clash). Additionally, the location of the helix is near critical residues (His21, Glu24) involved in zinc binding, so that a mutation near this region may abolish enzymatic activity.

In neurogenetics, not every DNA change causes disease! 📌 The ACMG/AMP (American College of Medical Genetics and Genomics...
26/04/2026

In neurogenetics, not every DNA change causes disease!

📌 The ACMG/AMP (American College of Medical Genetics and Genomics and the Association for Molecular Pathology) guidelines standardise how we classify genetic variants.

Variants are interpreted following the ACMG five‑tier classification system:

🔴 Pathogenic (The variant is conclusively disease‑causing based on robust evidence)
🟠 Likely Pathogenic (Strong evidence supports a disease‑causing role, but the evidence is not yet sufficient to reach definitive pathogenic status)
🟡 Variant of Uncertain Significance VUS (Insufficient or conflicting evidence to determine whether the variant is benign or pathogenic)
🟢 Likely Benign (Strong evidence suggests the variant does not cause disease, but not enough to be conclusive)
🔵 Benign (Conclusive evidence that the variant has no effect on disease)

🧬Duchenne Muscular Dystrophy (DMD) is a severe X-linked recessive neuromuscular disorder. In Egypt, it is reported to be...
23/04/2026

🧬Duchenne Muscular Dystrophy (DMD) is a severe X-linked recessive neuromuscular disorder. In Egypt, it is reported to be among the highest globally, estimated at 7.7 per 100,000 population!

One gene, one diagnosis, one chance for early intervention.

ضمور العضلات الدوشيني هو مرض وراثي بيأثر على الأعصاب والعضلات، متنحي ومرتبط بالكروموسوم اكس ، في مصر معدلاته من أعلى المعدلات عالميًا،
!حوالي 7.7 حالة لكل 100,000 نسمة

70% globally, 31% in Egyptian children, 35% consanguinity. The numbers speak for themselves!Arabic in the first comment
20/04/2026

70% globally, 31% in Egyptian children, 35% consanguinity. The numbers speak for themselves!

Arabic in the first comment

Dear colleagues, researchers, and physicians,We are excited to launch NeuroGene Nile (NGN) – the first Egyptian educatio...
19/04/2026

Dear colleagues, researchers, and physicians,

We are excited to launch NeuroGene Nile (NGN) – the first Egyptian educational platform dedicated to neurogenetics and neurodevelopmental disorders, seen through the lens of our own patients, our own genes, and our own clinical reality.

Who We Are!

Our team consists of Egyptian physicians specializing in medical genetics and biotechnologists specializing in molecular genetics, united by a common background in neuroscience at the postgraduate level.

We aim to:

1- Post challenging cases from our unit, covering clinical presentation alongside genetic findings.
2- Build the first comprehensive Egyptian reference for neurogenetic and neurodevelopmental disorders.
3- We will organize online courses, workshops, and panel discussions – bringing together geneticists, neurologists, pediatricians.

🧠The Rationale behind creating this platform is that in Egypt, neurodevelopmental disorders are frequently encountered in daily practice. However, a critical gap exists between clinicians (neurologists, pediatricians, psychiatrists) who evaluate patients and molecular geneticists who interpret the genomic data.

💡We created NeuroGene Nile (NGN) to serve as the bridge. We speak both languages – clinical and molecular. Through cases, educational courses, and panel discussions.

So that NGN is the platform where clinicians and molecular geneticists speak the same language, for every Egyptian child with a neurodevelopmental disorder 🧠

Address

Cairo
11311

Alerts

Be the first to know and let us send you an email when NeuroGene Nile posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share